-
11.发明授权Tumor-targeting gas-generating nanoparticle, method for preparing the same, and tumor-targeting nanoparticle for drug delivery using the same 有权肿瘤靶向产生气体的纳米颗粒，其制备方法和用于药物递送的肿瘤靶向纳米颗粒公开(公告)号：US09259395B2
公开(公告)日：2016-02-16
申请号：US13906963
申请日：2013-05-31
Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
Inventor： Ick Chan Kwon , Kwang Meyung Kim , Kuiwon Choi , Heebeom Koo , Hyun Su Min , Inchan Youn
CPC classification number: A61K9/5146 , A61K9/0004 , A61K9/0009 , A61K9/0019 , A61K9/5153 , A61K41/0028 , A61K47/6925 , A61K49/0032 , A61K49/0054 , A61K49/0093 , A61K49/222 , A61K49/225
Abstract: A tumor-targeting gas-generating nanoparticle, a method for preparing same and a tumor-targeting nanoparticle for drug delivery using same relate to a tumor-targeting gas-generating nanoparticle including a polycarbonate core and a amphiphilic coat, a method for preparing same and a tumor-targeting nanoparticle for drug delivery using same. Since a tumor-targeting gas-generating nanoparticle according to the present disclosure is accumulated in the tumor tissue in large quantity and generates strong ultrasound wave signals, it can be usefully used as a contrast agent for ultrasonic imaging.
Abstract translation: 肿瘤靶向产生气体的纳米颗粒，其制备方法和使用其的药物递送的肿瘤靶向纳米颗粒涉及包含聚碳酸酯芯和两亲性涂层的肿瘤靶向产生气体的纳米颗粒，其制备方法和 用于药物递送的肿瘤靶向纳米颗粒。 由于根据本发明的肿瘤靶向产生气体的纳米颗粒大量积聚在肿瘤组织中，并且产生强大的超声波信号，因此可以有效地用作超声成像造影剂。
-
12.发明公开公开(公告)号：US20240325550A1
公开(公告)日：2024-10-03
申请号：US18618258
申请日：2024-03-27
Inventor： HoWon J. Kim , In-San Kim , Jay S. Kim , Sun Hwa Kim , Ick Chan Kwon , Jong Won Lee , Yoo Soo Yang , Hong Yeol Yoon
IPC: A61K47/64 , A61P35/00 , C12N15/113
CPC classification number: A61K47/64 , A61P35/00 , C12N15/113 , C12N2310/14 , C12N2310/141
Abstract: Therapeutic compounds for inhibiting and reducing the expression of cell surface proteins and methods for treating cancer, inflammation, and diabetes using the therapeutic compounds.
-
公开(公告)号：US20190307794A1
公开(公告)日：2019-10-10
申请号：US16379523
申请日：2019-04-09
Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
Inventor： Yeon-Sun HONG , Hyo Suk Kim , Yoo Soo Yang , Sun Hwa Kim , In-San Kim , Ick Chan Kwon
IPC: A61K35/15 , C12N5/0786 , C12N5/0784 , C12N5/0775 , A61K9/127 , C12N5/00
Abstract: The present invention relates to a method of inducing trans-differentiating a first type of immune cell into a second type of immune cell comprising: isolating exosomes from the second type of immune cell that has undergone differentiation, and treating the first type of immune cell or a cell population including the first type of immune cell with the isolated exosomes in vitro.
-
公开(公告)号：US20190201538A1
公开(公告)日：2019-07-04
申请号：US15944025
申请日：2018-04-03
Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
Inventor： Kwangmeyung KIM , Ick Chan Kwon , Juho Park
CPC classification number: A61K47/546 , A61K41/0071 , A61K47/55 , A61K47/65 , A61K47/6929 , A61P35/00
Abstract: Disclosed is a tumor-targeting photosensitizer-drug conjugate, more particularly to one which exhibits superior specific activity for a tumor tissue, is effectively accumulated in the tumor tissue and exhibits the medicinal effect of an anticancer agent with little systemic toxicity as a DEVD peptide is cleaved by caspase-3 and released topically from a prodrug form.
-
15.发明申请公开(公告)号：US20140140934A1
公开(公告)日：2014-05-22
申请号：US14074865
申请日：2013-11-08
Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
Inventor： Kwang Meyung Kim , Ick Chan Kwon , Inchan Youn , Hyun Su Min , Hong Yeol Yoon , Jae Hyung Park
IPC: A61K49/22
CPC classification number: A61K49/223 , A61K49/0032 , A61K49/0069
Abstract: Disclosed is a liver tumor-targeting ultrasound contrast agent. The ultrasound contrast agent includes a gas-generating core and a hyaluronic acid shell. The ultrasound contrast agent can be specifically delivered to liver cells. This specific delivery enables easy differentiation between normal liver cells and liver tumor cells by ultrasound imaging. In addition, the ultrasound contrast agent is highly stable in aqueous condition and causes no cytotoxicity. Also disclosed is a method for preparing the ultrasound contrast agent.
Abstract translation: 公开了一种肝肿瘤靶向超声造影剂。 超声造影剂包括产气芯和透明质酸壳。 可以将超声造影剂特异性地递送至肝细胞。 这种特异性的传递使得通过超声成像能够容易地在正常肝细胞和肝肿瘤细胞之间进行分化。 此外，超声造影剂在水性条件下高度稳定，不产生细胞毒性。 还公开了一种制备超声造影剂的方法。
-
Patent Agency Ranking
16.发明申请TUMOR-TARGETING GAS-GENERATING NANOPARTICLE, METHOD FOR PREPARING THE SAME, AND TUMOR-TARGETING NANOPARTICLE FOR DRUG DELIVERY USING THE SAME 有权肿瘤靶向气体产生纳米颗粒，其制备方法和用于药物递送的肿瘤靶向纳米颗粒公开(公告)号：US20130323177A1
公开(公告)日：2013-12-05
申请号：US13906963
申请日：2013-05-31
Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
Inventor： Ick Chan Kwon , Kwang Meyung Kim , Kuiwon Choi , Heebeom Koo , Hyun Su Min , Inchan Youn
CPC classification number: A61K9/5146 , A61K9/0004 , A61K9/0009 , A61K9/0019 , A61K9/5153 , A61K41/0028 , A61K47/6925 , A61K49/0032 , A61K49/0054 , A61K49/0093 , A61K49/222 , A61K49/225
Abstract: A tumor-targeting gas-generating nanoparticle, a method for preparing same and a tumor-targeting nanoparticle for drug delivery using same relate to a tumor-targeting gas-generating nanoparticle including a polycarbonate core and a amphiphilic coat, a method for preparing same and a tumor-targeting nanoparticle for drug delivery using same. Since a tumor-targeting gas-generating nanoparticle according to the present disclosure is accumulated in the tumor tissue in large quantity and generates strong ultrasound wave signals, it can be usefully used as a contrast agent for ultrasonic imaging.
Abstract translation: 肿瘤靶向产生气体的纳米颗粒，其制备方法和使用其的药物递送的肿瘤靶向纳米颗粒涉及包含聚碳酸酯芯和两亲性涂层的肿瘤靶向产生气体的纳米颗粒，其制备方法和 用于药物递送的肿瘤靶向纳米颗粒。 由于根据本发明的肿瘤靶向产生气体的纳米颗粒大量积聚在肿瘤组织中，并且产生强大的超声波信号，因此可以有效地用作超声成像造影剂。
-
17.发明公开公开(公告)号：US20240191237A1
公开(公告)日：2024-06-13
申请号：US18407780
申请日：2024-01-09
Inventor： HoWon J. Kim , In-San Kim , Jay S. Kim , Sun Hwa Kim , Ick Chan Kwon , Jong Won Lee , Yoo Soo Yang , Hong Yeol Yoon
IPC: C12N15/113 , A61P35/00
CPC classification number: C12N15/1138 , A61P35/00 , C12N2310/11 , C12N2310/531
Abstract: Therapeutic compounds for red blood cell-mediated delivery of an active pharmaceutical ingredient to a target cell are described. The therapeutic compounds are configured to bind CD47 on the surface of a red blood cell and to be subsequently transferred to CD47 on the surface of the target cell, the therapeutic compound ultimately being internalized by the target cell via endocytosis. The target cell may be a cancer cell.
-
18.发明公开公开(公告)号：US20240043846A1
公开(公告)日：2024-02-08
申请号：US18057050
申请日：2022-11-18
Inventor： HoWon J. Kim , In-San Kim , Jay S. Kim , Sun Hwa Kim , Ick Chan Kwon , Jong Won Lee , Yoo Soo Yang , Hong Yeol Yoon
IPC: C12N15/113 , A61P35/00
CPC classification number: C12N15/1138 , A61P35/00 , C12N2310/11 , C12N2310/531
Abstract: Therapeutic compounds for red blood cell-mediated delivery of an active pharmaceutical ingredient to a target cell are described. The therapeutic compounds are configured to bind CD47 on the surface of a red blood cell and to be subsequently transferred to CD47 on the surface of the target cell, the therapeutic compound ultimately being internalized by the target cell via endocytosis. The target cell may be a cancer cell, a virus-infected cell, or a fibrotic cell.
-
公开(公告)号：US10557156B2
公开(公告)日：2020-02-11
申请号：US16026796
申请日：2018-07-03
Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
Inventor： Hak Suk Chung , Yu Hyun Ji , Jin Su An , Ick Chan Kwon , Eun Gyeong Yang
Abstract: A bacterium that constitutively produces monophosphoryl lipid A (MLA) and a method of producing MLA by using the bacterium may simply produce MLA and a derivative thereof without acid hydrolysis, reduce a probability of natural mutation, and increase yields of MLA and a derivative thereof by constitutive expression of the MLA and derivative thereof.
-
20.发明授权公开(公告)号：US10213515B2
公开(公告)日：2019-02-26
申请号：US15169493
申请日：2016-05-31
Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
Inventor： Kwangmeyung Kim , Ju Hee Ryu , Ick Chan Kwon , Man Kyu Shim , Hong Yeol Yoon
IPC: A61K51/00 , A61M36/14 , A61K49/00 , C07K9/00 , G01N33/574 , G01N33/58 , C07K5/11 , C07K5/107 , A61K47/54
Abstract: The present disclosure relates to a glycopeptide targeting cancer cells and a contrast agent kit containing the same. The glycopeptide is one wherein an azide reporting monosaccharide is bound to a substrate peptide. As the substrate peptide is specifically cleaved by cathepsin B in cancer cells, an azide reporting monosaccharide is expressed onto the cell surface via metabolic glycoengineering, thereby providing a target for action as a contrast agent. Accordingly, because the azide is exposed to the cell surface only by cathepsin B, as it is specifically expressed in cancer cells, in particular in metastatic cancer cells, while it is limitedly expressed in normal cells and is hardly excreted out the cells, the cancer cells can be selectively imaged by an azide-specific contrast agent.
-
-
-
-
-
-
-
-
-
Search Results
24
records
(took 0.019 seconds)
